In recent years, new drugs for the treatment of T2D have expanded to include glucagon-like peptide 1 receptor agonists (GLP-1RAs), dipeptidyl peptidase 4 inhibitors (DPP-4is), and sodium–glucose cotransporter 2 inhibitors (SGLT2is). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.